Prot # VX-950-C211: A Randomized, Open-Label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination with Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C Virus Infect